Daniel Albert Schmitt

US Patent:

20100271196, Oct 28, 2010

Filed:

Apr 23, 2009

Appl. No.:

12/428574

Inventors:

Daniel P. Schmitt - San Diego CA, US
Arlene Hasegawa - San Diego CA, US
Stephen Lachmayr - San Diego CA, US

Assignee:

QUALCOMM INCORPORATED - San Diego CA

International Classification:

B60Q 1/54

US Classification:

340466

Abstract:

Systems and methods to determine a speed limit violation by a vehicle. A locator device coupled to the vehicle receives GPS location coordinates from a satellite. The systems and methods determine the speed of the vehicle using the received coordinates or the functions of an engine control module. The speed limit of the segment of roadway on which the vehicle is traveling is identified based on the coordinates, and the vehicle speed is compared to the speed limit to determine whether the vehicle is violating the speed limit for the segment of roadway. The systems and methods alert any interested parties, such as the vehicle driver or a fleet manager, of the speed limit violation.

US Patent:

20210206757, Jul 8, 2021

Filed:

Mar 5, 2021

Appl. No.:

17/192968

Inventors:

- New York NY, US
Andrew Christopher Flick - Carlsbad CA, US
Daniel Wei-Shung Kung - Salem CT, US
Vincent Michael Lombardo - Carmel IN, US
James John Mousseau - Norwich CT, US
Daniel Copley Schmitt - Westerly RI, US
Mark Edward Schnute - Acton MA, US
Atli Thorarensen - Stow MA, US
John Isidro Trujillo - Ledyard CT, US
Rayomand Jal Unwalla - Bedford MA, US
Huixian Wu - East Lyme CT, US

Assignee:

Pfizer Inc. - New York NY

International Classification:

C07D 413/14
A61P 29/00
C07D 401/12
C07D 401/14
C07D 405/14
C07D 413/12
C07D 417/12
C07D 417/14
C07F 9/6558

Abstract:

The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B)or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.